18 November 2026
ECDC is publishing this rapid risk assessment due to a worsening epidemiological situation for carbapenem-resistant Enterobacterales (CRE) in the European Union (EU)/European Economic Area (EEA) which is leading to an increasing loss of treatment options. At the same time, the estimated incidence of bloodstream infections (BSIs) by carbapenem-resistant K. pneumoniae for the EU/EEA continues to increase. In this document, ECDC assesses the situation and proposes recommendations to EU/EEA countries. This assessment is intended for national public health authorities and healthcare providers in the EU/EEA.
Epidemiological situation
Recent EURGen-Net investigations and the survey of carbapenem-resistant Enterobacterales 2025 (CRE25 survey) show a further worsening epidemiological situation for CRE in the EU/EEA.
This includes a shift in carbapenemases in Klebsiella pneumoniae with an increasing proportion of NDM carbapenemases, increasing acquisition of the virulence factors yersiniabactin and aerobactin in K. pneumoniae, as well as increasing dissemination of Escherichia coli carrying blaOXA-244.
Based on these findings, the probability of further spread with escalating transmission of CRE in healthcare and community settings in the EU/EEA is high.
Risk assessment
Carbapenem-resistant Enterobacterales BSIs are associated with a high level of attributable mortality, primarily due to delays in administering effective antimicrobial therapy and the limited number of alternative treatment options.
Novel beta-lactam/beta-lactamase inhibitor combinations have been approved for use in the EU since 2016.
However, the increasing proportion of NDM carbapenemases in carbapenem-resistant K. pneumoniae has rapidly reduced the number of effective new treatment options.
Simultaneously, an increase in virulence markers in carbapenem-resistant K. pneumoniae may favour prolonged colonisation, a higher probability of infection and potentially more severe infections.
The impact of the spread of CRE can be mitigated by appropriate awareness, coordinated action at the national level, early laboratory detection and characterisation, enhanced infection prevention and control (IPC) measures, and antimicrobial stewardship.
However, the continued increase of CRE will not only result in negative treatment outcomes for individuals but can also negatively impact the quality and sustainable delivery of healthcare, resulting in a very high risk to patients requiring healthcare in the EU/EEA.
Recommendations
The following enhanced efforts are required to control and reduce harm related to the spread of CRE in the EU/EEA:
° Strengthen national coordination of CRE control measures and develop a national strategy for CRE control. This includes a national CRE management team and action plan for CRE.
° Improve IPC measures in healthcare facilities. Hand hygiene remains one of the most effective measures to interrupt transmission and should be prioritised alongside screening, contact precautions, communication, and training. Detailed IPC measures are outlined in the full Recommendations section below.
° Establish adequate laboratory capacity for rapid detection and characterisation of CRE, including phenotypic antimicrobial susceptibility testing and identification of carbapenemase genes, to enable targeted use of newly-approved antimicrobials.
° Strengthen genomic surveillance, including whole genome sequencing, as close as possible to real time, accompanied by systematic metadata to guide IPC measures by identifying sources of CRE outbreaks and delineating transmission chains.
° Apply antimicrobial stewardship to decrease selection pressure and preserve the effectiveness of the carbapenems and the newly approved antimicrobials. This includes national treatment guidelines and audits of their implementation. Ensure access to antimicrobials effective against NDM-producing Enterobacterales.
° Strengthen investment in research, including innovative approaches for CRE treatment and control.
What is new?
Revised risk assessment based on the latest European genomic surveillance results on carbapenem-resistant K. pneumoniae and E. coli from the recent CRE25 survey and related strengthened recommendations.
Source: European Centre for Disease Control and Prevention, https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-carbapenem-resistant-enterobacterales-fourth-update
____

No comments:
Post a Comment